Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, No. 110, Section 1, Jianguo N. Rd., Taichung, 402, Taiwan, Republic of China.
Clinical Laboratory, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China.
BMC Complement Altern Med. 2019 Aug 13;19(1):211. doi: 10.1186/s12906-019-2630-5.
Breast cancer is the leading cause of cancer-related death in women worldwide. Although traditional Chinese medicine (TCM) is commonly used by patients with breast cancer, little is known about TCM prescriptions for breast cancer. This study investigated the effects of a new TCM formula, T33, comprising Radix Kansui, Rheum rhabarbarum, Paeonia lactiflora, Jiangbanxia, and Zhigancao on breast cancer cells in vitro and in vivo.
To evaluate the effects of T33 on human breast cancer, HMEpiC, MDA-MB231 and MCF-7 cells were treated with different concentrations of T33 and then analyzed using MTT and Transwell migration assays. To elucidate the involvement of autophagy in the T33-induced death of MDA-MB231 and MCF-7 cells, immunofluorescence staining with LC3-II-specific antibodies was performed. Tumor xenografts were generated by subcutaneously injecting either MDA-MB231 or MCF-7 cells into BALB/c nude mice to determine the effects of T33 on these cell lines in vivo.
The experimental results revealed that 0.1 mg/mL, 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL T33 significantly inhibited the proliferation and invasion of MDA-MB231 and MCF-7 cells. Moreover, significant autophagy was observed in MDA-MB231 and MCF-7 cells in the presence of 2.5 mg/mL, 5 mg/mL and 10 mg/mL T33. An animal study further revealed that both low (200 mg/kg) and high (600 mg/kg) doses of T33 inhibited the proliferation of xenografted breast cancer cells in BALB/c nude mice.
These findings demonstrate for the first time that T33 has potential in the treatment of breast cancer owing to its antiproliferative effects and induction of autophagy.
乳腺癌是全球女性癌症相关死亡的主要原因。虽然传统中药(TCM)在乳腺癌患者中被广泛使用,但对于 TCM 处方治疗乳腺癌的了解甚少。本研究调查了一种新的 TCM 配方 T33(包括甘遂、大黄、白芍、姜半夏和炙甘草)对体外和体内乳腺癌细胞的影响。
为了评估 T33 对人乳腺癌的影响,用不同浓度的 T33 处理 HMEpiC、MDA-MB231 和 MCF-7 细胞,然后用 MTT 和 Transwell 迁移实验进行分析。为了阐明自噬在 T33 诱导 MDA-MB231 和 MCF-7 细胞死亡中的作用,用 LC3-II 特异性抗体进行免疫荧光染色。通过将 MDA-MB231 或 MCF-7 细胞皮下注射到 BALB/c 裸鼠中生成肿瘤异种移植,以确定 T33 在体内对这些细胞系的影响。
实验结果表明,0.1mg/mL、0.5mg/mL、2.5mg/mL、5mg/mL 和 10mg/mL 的 T33 显著抑制 MDA-MB231 和 MCF-7 细胞的增殖和侵袭。此外,在 2.5mg/mL、5mg/mL 和 10mg/mL 的 T33 存在下,观察到 MDA-MB231 和 MCF-7 细胞中明显的自噬。动物研究进一步表明,T33 的低(200mg/kg)和高(600mg/kg)剂量均抑制了 BALB/c 裸鼠异种移植乳腺癌细胞的增殖。
这些发现首次表明,T33 具有治疗乳腺癌的潜力,因为它具有抗增殖作用和诱导自噬作用。